Full Text
A Cost-Effectiveness Analysis of Biosimilar Infliximab (Inflectra®) For The Treatment of Psoriatic Arthritis In Nine European Countries

Abstract

Authors

F Rencz M Péntek L Gulacsi P Baji

Back to Volume 19, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×